14Apr/14

Biogen Idec to Present New Clinical Data from Its Robust Neurology Portfolio … – MarketWatch

April 14, 2014Monoclonal Anti-IL-2Rα Receptor Antibodiesadmin

Biogen Idec to Present New Clinical Data from Its Robust Neurology Portfolio …
MarketWatch
Daclizumab high-yield process (DAC HYP) is in late-stage clinical development for the treatment of RRMS, the most common form of MS. DAC HYP is a humanized monoclonal antibody that binds to CD25, a receptor subunit that is expressed at high levels on …
Company Update: Biogen Idec Inc (NASDAQ:BIIB) – Biogen Idec to Present New …Jutia Group

all 3 news articles »

14Apr/14

Biogen Idec to Present New Clinical Data from Its Robust Neurology Portfolio … – Business Wire (press release)

April 14, 2014Monoclonal Anti-IL-2Rα Receptor Antibodiesadmin

Biogen Idec to Present New Clinical Data from Its Robust Neurology Portfolio …
Business Wire (press release)
… beta-1a) and FAMPYRA® (prolonged-release fampridine tablets), as well as findings from the clinical programs of its MS pipeline candidates PLEGRIDY™ (peginterferon beta-1a), daclizumab high-yield process (DAC HYP) and Anti-LINGO-1 (BIIB033).

14Apr/14

92 Club: Bristol football fans to visit all 92 grounds for Invest In ME charity – Bristol Post

April 14, 2014Monoclonal Anti-CD20 Antibodiesadmin

Bristol Post92 Club: Bristol football fans to visit all 92 grounds for Invest In ME charityBristol PostMoney raised will go towards UK trials of the drug Rituximab. A 2,600-mile route is due to be completed in 92 hours of driving, spread out over the c…

13Apr/14

HIV Patients May Need More Frequent Immunizations – dailyRx

April 13, 2014Antibodiesadmin

HIV Patients May Need More Frequent ImmunizationsdailyRxRecently, a research team reviewed published studies and reported that protective antibodies in HIV-infected patients did not last as long after vaccination as they did in healthy people. They rec…

12Apr/14

VIDEO: IACFS/ME Conference – Summary of Research by Dr. Komaroff – ProHealth

April 12, 2014Monoclonal Anti-CD20 Antibodiesadmin

VIDEO: IACFS/ME Conference – Summary of Research by Dr. Komaroff
ProHealth
In terms of the cytokine changes that we’re seeing consistently over various labs all over the world as well as NK cell function, how can we use biologics in terms of the Norwegian study with Rituximab to make sense of any improvement in certain patients?

and more »

11Apr/14

Emerging therapies for relapsed/refractory CLL/SLL expected to offer efficacy … – The Pharma Letter

April 11, 2014Monoclonal Anti-CD20 Antibodiesadmin

The Pharma Letter

Emerging therapies for relapsed/refractory CLL/SLL expected to offer efficacy …
The Pharma Letter
It is expected that these agents will be added to rituximab-containing regimens, such as bendamustine (Teva Pharmaceutical Industries’ Treanda, Mundipharma’s Ribomustin/Levact, Symbio Pharmaceuticals/Eisai’s Treakisym) in combination with rituximab, …

11Apr/14

PolyTherics extends ThioBridge antibody drug conjugate collaboration with … – News-Medical.net

April 11, 2014Antibodiesadmin

PolyTherics extends ThioBridge antibody drug conjugate collaboration with …
News-Medical.net
MacroGenics has two antibody technology platforms, a Dual-Affinity Re-Targeting (DART™) bi-specific platform, in which a single recombinant molecule is able to target two different antigens, and Fc-optimized antibodies with improved effector function.

and more »

11Apr/14

HIV Vaccine train still crawls – Africa Science News Service

April 11, 2014Antibodiesadmin

HIV Vaccine train still crawls
Africa Science News Service
According to the National Institute of Communicable Diseases, scientists have tracked one woman’s reaction to HIV infection from stored samples of her blood and isolated the antibodies that she later developed. The study, by a consortium of scientists …

10Apr/14

Effects of a biologic agent in a patient with rheumatoid arthritis after … – 7thSpace Interactive (press release)

April 10, 2014Monoclonal Anti-CD20 Antibodiesadmin

Effects of a biologic agent in a patient with rheumatoid arthritis after …7thSpace Interactive (press release)The lymphoma went into complete remission after 6 courses of rituximab plus cyclophosphamide, hydroxydaunorubicin, vincristine, and predniso…

10Apr/14

Bendamustine plus rituximab noninferior to standard therapy in NHL, mantle … – Healio

April 10, 2014Monoclonal Anti-CD20 Antibodiesadmin

Bendamustine plus rituximab noninferior to standard therapy in NHL, mantle …
Healio
In patients with slowly progressing non-Hodgkin’s lymphoma or mantle cell lymphoma, a regimen of bendamustine and rituximab is noninferior to standard treatment in terms of response rate and safety profile, according to findings from the BRIGHT study.

Category Archives: Antibodies